{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:11:45Z","timestamp":1773666705010,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T00:00:00Z","timestamp":1473897600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81072135"],"award-info":[{"award-number":["81072135"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81372801"],"award-info":[{"award-number":["81372801"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Natural Science Foundation of China (CN)","award":["81572570"],"award-info":[{"award-number":["81572570"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s13277-016-5297-2","type":"journal-article","created":{"date-parts":[[2016,9,14]],"date-time":"2016-09-14T18:01:13Z","timestamp":1473876073000},"page":"14745-14755","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Geldanamycin, an inhibitor of Hsp90, increases paclitaxel-mediated toxicity in ovarian cancer cells through sustained activation of the p38\/H2AX axis"],"prefix":"10.1007","volume":"37","author":[{"given":"Qingqing","family":"Mo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinglei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pingbo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,15]]},"reference":[{"issue":"4","key":"5297_CR1","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/AOG.0b013e31819cda77","volume":"113","author":"E Partridge","year":"2009","unstructured":"Partridge E et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol. 2009;113(4):775\u201382.","journal-title":"Obstet Gynecol"},{"issue":"4","key":"5297_CR2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2217\/fon.11.14","volume":"7","author":"K Lassi","year":"2011","unstructured":"Lassi K, Dawson NA. Drug development for metastatic castration-resistant prostate cancer: current status and future perspectives. Future Oncol. 2011;7(4):551\u20138.","journal-title":"Future Oncol"},{"issue":"73","key":"5297_CR3","doi-asserted-by":"crossref","first-page":"73ps8","DOI":"10.1126\/scitranslmed.3002137","volume":"3","author":"TJ Merkel","year":"2011","unstructured":"Merkel TJ, DeSimone JM. Dodging drug-resistant cancer with diamonds. Sci Transl Med. 2011;3(73):73ps8.","journal-title":"Sci Transl Med"},{"issue":"3","key":"5297_CR4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","volume":"5","author":"G Szakacs","year":"2006","unstructured":"Szakacs G et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5(3):219\u201334.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"5297_CR5","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.coph.2008.06.015","volume":"8","author":"T Taldone","year":"2008","unstructured":"Taldone T et al. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol. 2008;8(4):370\u20134.","journal-title":"Curr Opin Pharmacol"},{"issue":"10","key":"5297_CR6","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc1716","volume":"5","author":"L Whitesell","year":"2005","unstructured":"Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5(10):761\u201372.","journal-title":"Nat Rev Cancer"},{"issue":"1\u20133","key":"5297_CR7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0014-5793(04)00229-7","volume":"562","author":"AS Sreedhar","year":"2004","unstructured":"Sreedhar AS et al. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett. 2004;562(1\u20133):11\u20135.","journal-title":"FEBS Lett"},{"issue":"10","key":"5297_CR8","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1039\/c3np70012g","volume":"30","author":"J Franke","year":"2013","unstructured":"Franke J et al. Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy. Nat Prod Rep. 2013;30(10):1299\u2013323.","journal-title":"Nat Prod Rep"},{"issue":"6956","key":"5297_CR9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature01913","volume":"425","author":"A Kamal","year":"2003","unstructured":"Kamal A et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003;425(6956):407\u201310.","journal-title":"Nature"},{"issue":"4","key":"5297_CR10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ctrv.2012.10.001","volume":"39","author":"DS Hong","year":"2013","unstructured":"Hong DS et al. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev. 2013;39(4):375\u201387.","journal-title":"Cancer Treat Rev"},{"issue":"19","key":"5297_CR11","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1016\/j.febslet.2007.05.040","volume":"581","author":"MV Powers","year":"2007","unstructured":"Powers MV, Workman P. Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett. 2007;581(19):3758\u201369.","journal-title":"FEBS Lett"},{"issue":"8","key":"5297_CR12","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s00109-004-0549-9","volume":"82","author":"H Zhang","year":"2004","unstructured":"Zhang H, Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med (Berl). 2004;82(8):488\u201399.","journal-title":"J Mol Med (Berl)"},{"issue":"16","key":"5297_CR13","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1093\/emboj\/19.16.4383","volume":"19","author":"C Prodromou","year":"2000","unstructured":"Prodromou C et al. The ATPase cycle of Hsp90 drives a molecular \u2018clamp\u2019 via transient dimerization of the N-terminal domains. EMBO J. 2000;19(16):4383\u201392.","journal-title":"EMBO J"},{"issue":"2","key":"5297_CR14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10495-010-0554-0","volume":"16","author":"J Ravindran","year":"2011","unstructured":"Ravindran J et al. Modulation of ROS\/MAPK signaling pathways by okadaic acid leads to cell death via, mitochondrial mediated caspase-dependent mechanism. Apoptosis. 2011;16(2):145\u201361.","journal-title":"Apoptosis"},{"issue":"3","key":"5297_CR15","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/jcp.21713","volume":"219","author":"WH Liu","year":"2009","unstructured":"Liu WH, Cheng YC, Chang LS. ROS-mediated p38alpha MAPK activation and ERK inactivation responsible for upregulation of Fas and FasL and autocrine Fas-mediated cell death in Taiwan cobra phospholipase A(2)-treated U937 cells. J Cell Physiol. 2009;219(3):642\u201351.","journal-title":"J Cell Physiol"},{"issue":"4","key":"5297_CR16","doi-asserted-by":"crossref","first-page":"582","DOI":"10.4149\/neo_2015_070","volume":"62","author":"HQ Bu","year":"2015","unstructured":"Bu HQ et al. Induction of apoptosis by capsaicin in hepatocellular cancer cell line SMMC-7721 is mediated through ROS generation and activation of JNK and p38 MAPK pathways. Neoplasma. 2015;62(4):582\u201391.","journal-title":"Neoplasma"},{"issue":"1","key":"5297_CR17","first-page":"e464","volume":"2","author":"H Liu","year":"2015","unstructured":"Liu H, He J, Yang J. Tumor cell p38 MAPK: a trigger of cancer bone osteolysis. Cancer Cell Microenviron. 2015;2(1):e464.","journal-title":"Cancer Cell Microenviron"},{"issue":"5","key":"5297_CR18","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/mc.22331","volume":"55","author":"HG Kim","year":"2015","unstructured":"Kim HG et al. p38alpha MAPK is required for arsenic-induced cell transformation. Mol Carcinog. 2015;55(5):910\u20137.","journal-title":"Mol Carcinog"},{"issue":"9","key":"5297_CR19","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.bbamcr.2010.12.012","volume":"1813","author":"A Plotnikov","year":"2011","unstructured":"Plotnikov A et al. The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim Biophys Acta. 2011;1813(9):1619\u201333.","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"5297_CR20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/mc.22280","volume":"55","author":"Y Dong","year":"2015","unstructured":"Dong Y et al. Involvement of ROS-p38-H2AX axis in novel curcumin analogues-induced apoptosis in breast cancer cells. Mol Carcinog. 2015;55(4):323\u201334.","journal-title":"Mol Carcinog"},{"issue":"2","key":"5297_CR21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.toxlet.2008.04.004","volume":"179","author":"SJ Chiu","year":"2008","unstructured":"Chiu SJ et al. Regulation of gamma-H2AX and securin contribute to apoptosis by oxaliplatin via a p38 mitogen-activated protein kinase-dependent pathway in human colorectal cancer cells. Toxicol Lett. 2008;179(2):63\u201370.","journal-title":"Toxicol Lett"},{"issue":"18","key":"5297_CR22","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1016\/j.febslet.2008.06.051","volume":"582","author":"C Lu","year":"2008","unstructured":"Lu C et al. Serum starvation induces H2AX phosphorylation to regulate apoptosis via p38 MAPK pathway. FEBS Lett. 2008;582(18):2703\u20138.","journal-title":"FEBS Lett"},{"issue":"2","key":"5297_CR23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.abb.2007.02.014","volume":"461","author":"A Dey","year":"2007","unstructured":"Dey A, Cederbaum AI. Geldanamycin, an inhibitor of Hsp90 increases cytochrome P450 2E1 mediated toxicity in HepG2 cells through sustained activation of the p38MAPK pathway. Arch Biochem Biophys. 2007;461(2):275\u201386.","journal-title":"Arch Biochem Biophys"},{"issue":"8","key":"5297_CR24","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2887","volume":"10","author":"J Trepel","year":"2010","unstructured":"Trepel J et al. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010;10(8):537\u201349.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"5297_CR25","first-page":"89","volume":"1816","author":"AA Khalil","year":"2011","unstructured":"Khalil AA et al. Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets? Biochim Biophys Acta. 2011;1816(2):89\u2013104.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"5297_CR26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34\u201343.","journal-title":"N Engl J Med"},{"issue":"2","key":"5297_CR27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ctrv.2005.12.010","volume":"32","author":"N Andre","year":"2006","unstructured":"Andre N, Meille C. Taxanes in paediatric oncology: and now? Cancer Treat Rev. 2006;32(2):65\u201373.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"5297_CR28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12079-011-0121-7","volume":"5","author":"LJ Crawford","year":"2011","unstructured":"Crawford LJ, Walker B, Irvine AE. Proteasome inhibitors in cancer therapy. J Cell Commun Signal. 2011;5(2):101\u201310.","journal-title":"J Cell Commun Signal"},{"issue":"1","key":"5297_CR29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bbrc.2011.10.054","volume":"415","author":"P Singh","year":"2011","unstructured":"Singh P et al. Inhibition of autophagy stimulate molecular iodine-induced apoptosis in hormone independent breast tumors. Biochem Biophys Res Commun. 2011;415(1):181\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"5297_CR30","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1158\/1535-7163.MCT-11-0497","volume":"10","author":"JH Cheong","year":"2011","unstructured":"Cheong JH et al. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther. 2011;10(12):2350\u201362.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"5297_CR31","first-page":"84","volume":"5","author":"F Yao","year":"2012","unstructured":"Yao F et al. An autophagy inhibitor enhances the inhibition of cell proliferation induced by a proteasome inhibitor in MCF-7 cells. Mol Med Rep. 2012;5(1):84\u20138.","journal-title":"Mol Med Rep"},{"key":"5297_CR32","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/3-540-29717-0_11","volume":"172","author":"L Neckers","year":"2006","unstructured":"Neckers L. Chaperoning oncogenes: Hsp90 as a target of geldanamycin. Handb Exp Pharmacol. 2006;172:259\u201377.","journal-title":"Handb Exp Pharmacol"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-016-5297-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-016-5297-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-016-5297-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T18:48:34Z","timestamp":1498330114000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-016-5297-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,15]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["5297"],"URL":"https:\/\/doi.org\/10.1007\/s13277-016-5297-2","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,15]]}}}